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Abstract 1 
Background: PREDICT is a widely-used online prognostication and treatment benefit tool for 2 
patients with early stage breast cancer. The aim of this study is to conduct an independent 3 
validation exercise of the most up-to-date version of the PREDICT algorithm (version 2) 4 
using real-world outcomes from the Scottish population of women with breast cancer. 5 
Methods: Patient data were obtained for all Scottish Cancer Registry (SCR) records with a 6 
diagnosis of primary invasive breast cancer diagnosed in the period between January 2001 7 
and December 2015.Prognostic scores were calculated using the PREDICT version 2 8 
algorithm. External validity was assessed by statistical analysis of discrimination and 9 
calibration. Discrimination was assessed by area under the receiver-operator curve (AUC). 10 
Calibration was assessed by comparing the predicted number of deaths to the observed 11 
number of deaths across relevant sub-groups.  12 
Results: 40,444 eligible cases were selected from 61,437 individual records. AUC statistics 13 
ranged from 0.74 to 0.77. Calibration results showed relatively close agreement between 14 
predicted and observed deaths. The 5 year complete follow-up sample reported some 15 
overestimation (11.5%) while the 10-year complete follow-up sample displayed more limited 16 
overestimation (1.7%). 17 
Conclusion: Validation results suggest that the PREDICT tool remains essentially relevant 18 
for contemporary patients with early stage breast cancer.  19 
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Background 1 
PREDICT is an online prognostication and treatment benefit tool for patients with early stage 2 
breast cancer (1). The PREDICT online tool aims to help inform clinician and patient 3 
decisions about adjuvant therapy following breast cancer surgery. Provided with input of a 4 
patient’s clinical characteristics, PREDICT provides personalised prognostic information 5 
displayed as 5-year and 10-year overall survival estimates, both with and without adjuvant 6 
therapies (chemotherapy, hormone therapy and trastuzumab). Results are presented both in 7 
textual format using a frequency based description of risk, and graphically in the form of bar 8 
charts with percentages labelled (http://www.predict.nhs.uk/). The PREDICT online tool is 9 
popular in the UK and worldwide with 20,000 visits reported in a single month (2). 10 
The algorithm behind the online tool was derived primarily from data obtained from the 11 
Eastern Cancer Registration and Information Centre (ECRIC) registry in the United Kingdom 12 
(east of England). Treatment effectiveness estimates are taken from the Early Breast 13 
Cancer Trialists’ Collaborative Group (EBCTCG) meta-analyses of clinical trials (3). The first 14 
online version of the tool was published in 2010 (1) (v1). A series of updates made since the 15 
launch have added new prognostic variables and refined the algorithm’s predictions. The 16 
first update published in 2012 (4), added HER2 status as a prognostic marker and allowed 17 
calculation of Trastuzumab treatment benefit estimates (v.1.2). In 2014, the tumour 18 
proliferative marker Ki-67 was added as an optional prognostic variable (5) (v1.3). The most 19 
recent update, in 2017, refined the model by including age at diagnosis in the breast cancer-20 
specific death prediction as well as recoding tumour size and nodal status variables (v2) (2). 21 
The aim of our study is to conduct an independent validation exercise of the most up-to-date 22 
version of the PREDICT algorithm available (v2) using real-world outcomes from the 23 
Scottish population of women with breast cancer. 24 
The validity of a prognostic model refers to its ability to accurately predict outcomes for 25 
patients, both in the sample from which it was derived (internal validity) and in other 26 
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populations to which it can be applied (external validity). This study is concerned with 1 
external validity and addresses this issue through statistical analysis of the two main 2 
performance variables, discrimination and calibration (Wyatt & Altman 1995). The reporting 3 
of this validation study follows the “transparent reporting of a multivariable prediction model 4 
for individual prognosis or diagnosis” (TRIPOD) guideline (6). 5 
The high-quality routine data available in Scotland over a long time period allow an 6 
assessment of external validity that is greater in scope than previous external validation 7 
studies of PREDICT (1, 2, 4). Validation is confined to mortality estimates; treatment benefit 8 
is not further considered here as this would require different study designs to provide robust 9 
causal inference. 10 
Methods 11 
Patient Data 12 
Patient level data were transferred into the National Services Scotland National Safe Haven 13 
as an extract from the Scottish Cancer Registry (SCR). SCR is a population-based registry 14 
that covers all residents of Scotland (population approximately 5.5 million). National Records 15 
of Scotland provides notification of deaths for registry records. All records in the registry with 16 
a diagnosis of primary invasive breast cancer (ICD-10 C50) diagnosed in the period between 17 
January 2001 and December 2015 were retrieved for analysis. Vital status was recorded up 18 
to 1st February 2017 in the analysis extract. Deaths due to breast cancer were defined in 19 
accordance with the ICD-10 coding system for causes of death, recorded either as the 20 
underlying cause of death or one of three secondary causes of death on death notifications. 21 
In cases for which there were multiple records of primary breast cancer for the same 22 
individual patient records of non-first occurrences of breast cancer were excluded. 23 
Prognostic factors available in the registry extract included: age at diagnosis, number of 24 
lymph nodes examined and number positive, tumour size (maximum pathological diameter 25 
in mm), tumour histological grade (categorical: 1-3), mode of detection (screen-detected or 26 
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symptomatic), estrogen receptor (ER) status, and Her2 status. Treatment status was 1 
available in relation to chemotherapy use (binary) and hormone therapy use (binary). 2 
Records indicated whether treatment was started or not but did not include information about 3 
treatment completion.  4 
This validation analysis followed closely the approaches taken in previous validation studies 5 
of PREDICT (1, 2, 7) in order to allow comparison of the results. Additional sensitivity 6 
analyses, further described below, have been conducted based on unique features of the 7 
SCR data. 8 
The data displayed a high level of completeness of all of the variables needed as inputs for 9 
the PREDICT model with the exception of HER2 status, trastuzumab use and Ki-67 status. 10 
Ki-67 status is not recorded in these data because this marker has not been in routine use in 11 
Scotland therefore all cases were assigned to the “unknown” category for this variable. 12 
HER2 status is only recorded from 2009. Cases with missing data for HER2 were assigned 13 
the “unknown” category. This includes 100% of cases from before 2009. The PREDICT 14 
algorithm handles “unknown” values in these categories by averaging across the available 15 
categories weighted by their frequency in the development data. Furthermore, trastuzumab 16 
use is not routinely recorded within the SCR therefore it was assumed that trastuzumab was 17 
used for all cases with a recorded positive HER2 status and chemotherapy use and in no 18 
cases with a recorded negative or unknown status, or positive status with no chemotherapy 19 
use. Recent Scottish clinical audit data submitted to a national review reported transtuzumab 20 
use for eligible HER2 positive cases is greater than 90% in the majority of health boards (8). 21 
Chemotherapy use is recorded as a binary variable in SCR therefore the generation of 22 
chemotherapy is unknown. It was assumed to be second generation for all cases in the 23 
primary analysis. A sensitivity analysis varied this assumption to instead assume third 24 
generation chemotherapy for cases which are node positive, under 70 years of age and 25 
diagnosed during or after 2006.  26 
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PREDICT 10-year prognostic index scores were calculated for each individual case based 1 
on their recorded risk factor information using the algorithms supplied by the PREDICT 2 
authors (version 2). The scores include the probability of death from all causes, probability of 3 
death from breast cancer accounting for competing risk, and adjuvant therapy benefit as the 4 
percentage point reduction in the probability of all-cause mortality for each adjuvant therapy. 5 
Details of the calculation of the prognostic index are available in Candido Dos Reis et al (2).  6 
Cases were excluded if the patient was male, had advanced cancer (clinical M stage = 1), 7 
did not receive surgery or received neoadjuvant therapy (chemotherapy or hormone therapy 8 
recorded prior to date of surgery). Two sensitivity analyses were conducted to test sensitivity 9 
of calibration results to the selection criteria applied: [1] Adding an exclusion criteria that the 10 
number of lymph nodes examined in node negative cases must be four or more; [2] 11 
exclusion of T4 cases as well as neo-adjuvant cases. The additional exclusion criterion in [1] 12 
creates a sample selected in an equivalent manner to that reported in the development and 13 
earlier validation studies of the PREDICT model (1, 7). Data used in earlier studies were 14 
collected in a period prior to widespread use of sentinel node biopsy and therefore 15 
compared with the patients included in this dataset a larger number of nodes were 16 
examined. 17 
 18 
Cases in which neoadjuvant therapy was used were excluded in the primary analysis 19 
because neoadjuvant therapy can alter the prognostic variables recorded in registry data 20 
(e.g. tumour size may be reduced) and PREDICT is less relevant as a tool for estimating 21 
treatment benefit in such circumstances. Neoadjuvant therapy has become more common in 22 
recent years, therefore we believe that this exclusion criterion is important for the validation 23 
of PREDICT, although it has not been applied in previous analyses. 24 
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Statistical Methods 1 
Discrimination of the PREDICT score as a prognostic index was assessed by calculating the 2 
area under the receiver-operator curve (ROC) (AUC) for both 5 and 10-year all-cause 3 
mortality, and 5 and 10-year breast cancer-specific mortality. AUC statistics were calculated 4 
separately for ER+ and ER- cases. In addition, Harrell’s c-statistic (9) was calculated in the 5 
primary analysis sample. This is a concordance statistic which can be used with right-6 
censored survival data such as those available in this data set. 7 
Assessment of calibration was made by comparing the predicted outcomes to the observed 8 
outcomes in the validation data. This is reported as the total numbers of deaths predicted 9 
and total number of deaths observed in the full sample, and also in selected sub-groups 10 
(following Wishart et al (1)). 5 year and 10 year periods of complete follow-up were 11 
considered. In each case, predicted probabilities of mortality were summed across all 12 
individuals for whom complete follow-up was available for the specified period. A third 13 
analysis considered individual specific follow-up periods up to the time of censoring. 14 
Predicted probabilities of mortality were calculated using the PREDICT algorithm for each 15 
individual’s own potential follow-up time in this analysis. Total numbers of deaths were 16 
counted for the selected samples within each of the specified follow-up periods. Differences 17 
are reported as relative differences, (Predicted - Observed)/Observed, over 5 years, 10 18 
years and individual potential follow-up times. Absolute differences (% mortality predicted - 19 
% mortality observed) are reported for 5 year and 10 year complete follow-up. Results are 20 
reported for all deaths, and separately for breast cancer deaths only (Supplementary 21 
Appendix). The sub-groups examined are based on univariate groupings on the variables 22 
and levels as described in table S1. 23 
A goodness-of-fit test (Hosmer-Lemeshow test with 10 groups) for survival data was 24 
calculated (10). This test is based on differences in observed and predicted outcomes in 25 
deciles of the prognostic score and a Chi-squared test statistic. Note that we would expect 26 
this test to reject the null hypothesis of no difference in observed and predicted outcomes 27 
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across deciles of score. Small differences in mortality rates could achieve statistical 1 
significance due to the very large sample size. Calibration by decile of PREDICT score is 2 
also presented graphically as a calibration plot.  3 
A major reason to expect worse calibration in this validation sample compared to the original 4 
sample is the time periods in which the cohorts were diagnosed. All patients in the original 5 
derivation sample were diagnosed between 1999 and 2003 while this validation sample 6 
spans a period from 2001 to 2015. To explore the impact of such time trends a sensitivity 7 
analysis was conducted repeating the calculation of calibration statistics on subsets of the 8 
data including cases diagnosed from 2001-2005, 2006-2010 and 2011-2015 respectively. 9 
To address potential bias from missing prognostic information, multiple imputation analysis 10 
was conducted for all missing prognostic factors. Multiple imputation created 10 data sets 11 
using chained equations (MICE) (11) .  PREDICT scores were calculated for observations in 12 
all imputed datasets. The calibration analysis was repeated with the imputed datasets and 13 
the expected and observed deaths were calculated with combination of results across 14 
imputed datasets according to Rubin’s rules (12).  15 
Results 16 
Sample selection 17 
63,116 records were retrieved from the registry. Following removal of ‘duplicate’ records 18 
(see Supplementary appendix for details) and application of the exclusion criteria a total of 19 
45,789 cases (72.5%) remained in the primary analysis using multiple imputation of missing 20 
data. The process is detailed in figure 1.  The final sample size of complete cases was 21 
40,444. 12% of otherwise eligible cases contained missing prognostic variable data. In most 22 
cases only a single variable was missing. 23 
The characteristics of the complete case sample are described in table 1 alongside the 24 
same reported descriptive statistics of the ECRIC cohort (1). Notable differences between 25 
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ECRIC and SCR samples were the somewhat older age distribution, slightly higher use of 1 
adjuvant chemotherapy and a higher proportion of screen detected cases for SCR. There 2 
was also a lower proportion of deaths attributed to breast cancer in the SCR data. This may 3 
be partly explained by a higher all-cause mortality rate in the Scottish population compared 4 
to the East of England population. The age-standardised mortality rate for females was 5 
1025.5 in Scotland compared to 815.6 in East of England in 2015 (13).   6 
[Figure 1 here] 7 
[Table 1 here] 8 
Discrimination 9 
.  Across ER-positive and ER-negative cases AUC statistics ranged from 0.75 to 0.78. 10 
Performance was similar to that reported in the original data and previous validation exercise 11 
(0.76-0.78) (2). The associated Harrell’s c-statistics were 0.759 for ER-positive at 5 years, 12 
0.738 for ER-negative at 5 years, 0.749 for ER-positive at 10 years and 0.730 for ER-13 
negative at 10 years respectively. AUC statistics for alternative sample selections and 14 
outcomes considered across all sensitivity analyses are shown in table S2. ROC curves and 15 
the associated AUC statistics are displayed in figure 2 for the complete case analysis. 16 
[Figure 2 here] 17 
Calibration 18 
Calibration assessed the accuracy of the probability estimates across specific univariate 19 
groupings of individual cases. Total number of predicted and observed deaths in the full 20 
sample and in sub-groups according to the defined variables and levels are reported in table 21 
2. 22 
 [Table 2 here] 23 
 24 
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. The 5 year complete follow-up sample show a general pattern of some overestimation of 1 
mortality. Overall expected mortality was 5.44% higher relative to observed mortality. In 2 
contrast. the 10-year complete follow-up sample showed a small degree of underestimation 3 
(-1.96%). In absolute terms, the predicted mortality was 0.79% above observed over 5 years 4 
and -0.6% lower over 10 years. In the full sample, using all lengths of follow-up (Table S3), 5 
calibration results showed a slightly larger degree of overestimation compared to the 5-year 6 
complete follow-up (11.1%). 7 
The degree of overestimation varied between groups, usually between 10-25%. Expected 8 
mortality was less than observed for the over 75 age group and grade I cases. Calibration 9 
was relatively poor in the group of patients with very large tumour size (>50mm), cases with 10 
very large numbers of nodes involved (10+) and for younger age groups (<35, 35-49, 50-64).  11 
Predicted and observed numbers of deaths were also calculated by decile of PREDICT 12 
score. The results are displayed as a calibration plot in figure 3 (complete case only). The 13 
Hosmer-Lemeshow test statistic was 49.951 (P<0.001) for 5 year follow-up and 13.449 14 
(P=0.1433) for 10 year follow-up respectively. The figure shows that calibration was very 15 
good for lower deciles of PREDICT score and less good for the highest deciles. Calibration 16 
across all deciles was good for cases with 10 years of complete follow-up. 17 
[Figure 3 here] 18 
Calibration results from the sensitivity analyses are presented in the Supplementary 19 
Appendix. The results using complete case data (Table S4) showed slightly worse 20 
calibration compared to the primary analysis using multiple imputation . Results were 21 
relatively insensitive to using alternative chemotherapy assumptions (Table S5), exclusion of 22 
node negative cases with less than four nodes sampled (Table S6) or exclusion of T4 cases 23 
(Table S7). Calibration in relation to breast cancer specific mortality appeared to be superior 24 
to calibration than for all-cause mortality (Table S8). For breast cancer specific mortality, 25 
total predicted mortality was only 2% above observed mortality over 5 year complete follow-26 
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up and 4.7% below observed mortality over 10 year complete follow-up. Calibration was 1 
relatively poor across sub-groups of age and grade and relatively good across other sub-2 
groups of other variables.  3 
The sensitivity analysis assessing calibration of PREDICT in cohorts diagnosed in the time 4 
periods 2001-2005, 2006-2010 and 2011-2015 displayed an apparent time trend in survival 5 
outcomes (Table S9-S11). In the 2001-2005 cohort predicted mortality was slightly lower 6 
than observed mortality while in the 2006-2010 and 2011-2015 the predicted mortality was 7 
higher than the observed. 5 year mortality was underestimated by 6.9% in the first cohort, 8 
then overestimated by 17.3% and 33.4% in the two subsequent cohorts. Likewise in relation 9 
to breast-cancer specific mortality (Table S12-S14) there was underestimation of 12% in the 10 
first cohort and overestimation of 14.9% and 22.4% in the second and third cohorts.  11 
Conclusions 12 
In this validation exercise of the PREDICT prognostication tool using an external dataset 13 
good performance was demonstrated with regards to both discrimination and calibration, 14 
comparable to that reported in the derivation and previous validation data.  15 
The key strength of this validation study is the suitability of the data in terms of both quality 16 
and quantity for addressing the research question. The large sample size drawn from the 17 
population-based SCR, which is eight times the previous validation samples combined, 18 
improves the precision of the results considerably and also allows an assessment of the 19 
generalisability of the model to the full population in whom it may be applied. The dataset 20 
includes cases diagnosed from 2001 to 2015, allowing its performance in more recent cases 21 
to be studied. All cases were followed-up until 2017 therefore cases diagnosed earlier in the 22 
period have a long duration of follow-up. 23 
There are some limitations to this study as a validation exercise. No data were available for 24 
some input parameters; Her2 (before 2009), trastuzumab use, Ki-67 status and generation 25 
of chemotherapy used. The PREDICT algorithm allows for unknown Ki-67 or Her2 status. 26 
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Generation of chemotherapy and trastuzumab use were based on assumptions. Alternative 1 
assumptions were explored in a sensitivity analysis which suggests these assumptions were 2 
not critical in influencing the results. This analysis cannot assess calibration with regards to 3 
Ki-67 status or the potential benefits of including this variable in relation to discrimination. A 4 
limitation of the PREDICT model is that is not suitable for providing prognostic estimates in 5 
neoadjuvant treated patients. Exclusion of these cases from the validation sample affects 6 
the composition of sample compared to the derivation sample because neoadjuvant treated 7 
patients are predominantly those with moderately poor prognosis. This may improve or 8 
worsen model performance depending on if the model performs relatively better or worse for 9 
these particular patients.  10 
Calibration was more accurate for some sub-groups than others. In particular, calibration 11 
was relatively poor for younger women (35-49, 50-64) and relatively good for older women. 12 
This is consistent with the results of a validation study performed in a cohort of women aged 13 
65 years or older in the Netherlands (14). Some overestimation for 10-year follow-up was 14 
observed in the Netherlands cohort while some underestimation was observed in this cohort. 15 
These differences may largely reflect differences in age-specific all-cause mortality rates 16 
between these settings; Scotland, the Netherlands and the East of England.   17 
Missing data on individual prognostic variables creates some potential for bias. This has 18 
been partially addressed by using multiple imputation. However, this relies upon 19 
assumptions regarding the pattern of missingness, assumed to be random conditional on 20 
observed covariates, and appropriateness of the imputation model. The proportion of cases 21 
with any amount of missing data was 12%, which is relatively modest.  22 
The validation results presented in this analysis provides greater confidence in the accuracy 23 
of the information given by the PREDICT online tool compared to previous validation 24 
studies. Calibration in the overall population appears to be sufficient for decision making 25 
purposes. In the Scottish context, version 2 of PREDICT is suitable for providing prognosis 26 
and treatment benefit estimates for patients with early breast cancer.  27 
13 
 
There is some evidence of predictions overestimating mortality for contemporary patients. It 1 
should be noted that each percentage point overestimation of absolute mortality risk will 2 
result in a fraction of a percentage point reduction in adjuvant chemotherapy benefit 3 
estimates (approximately 0 to 1/3 of a percentage point reduction, depending on whether 4 
breast cancer mortality and/or other causes of mortality are overestimated). Exploratory 5 
results suggest that predictions may become less well calibrated for the most recently 6 
diagnosed cohorts (an example of ‘calibration drift’ (15)). This issue is common across 7 
prognostic models and is likely to be of particular relevance in early breast cancer because 8 
of the continuing introduction of new interventions. If clinically relevant, this could potentially 9 
be addressed by an update of the PREDICT model – a version 3 - with more recent data 10 
used to derive the algorithm’s parameters. Researchers developing and validating 11 
prognostic models must strike a balance between using data with longer follow-up, 12 
necessarily from cohorts diagnosed further in the past, and using the most recent data, for 13 
which follow-up will consequently be shorter. The correct balance will need careful 14 
consideration in any future prognostic models in early breast cancer given the potential for 15 
calibration drift in this setting. 16 
A limitation of validation studies is that they do not provide a full investigation of the clinical 17 
utility or cost-effectiveness of using the prognostic model, however accurate it may be. A 18 
decision analysis or economic evaluation of use of prognostic models in this setting should 19 
therefore be a research priority. This could help to clarify the clinical and cost effectiveness 20 
of existing and future alternative prognostic models as well as the addition of new 21 
information such as genomic data.   22 
Validation of prognostic models is critical for both providing the necessary evidence for 23 
adoption into clinical practice (15) and for driving continuing improvement in prognostic 24 
information. This study provides large scale investigation of validity of the PREDICT 25 
prognostic model for early breast cancer. The results of this investigation suggest that it 26 
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remains essentially relevant for contemporary patients being diagnosed and managed with 1 
invasive breast cancer. 2 
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Figure Title and Legends 
 
Figure 1 – Sample selection flow diagram 
 
Figure 2 - ROC curves, ER+ (left) and ER- (right) cases at 5 years (top) and 10 years 
(bottom) follow-up  
ROC: Receiver-Operator Curve 
 
Figure 3 - Calibration plots - deciles of PREDICT score, 5 years (above) and 10 years 
(below) all-cause mortality 
 
Table 1 - Characteristics of derivation and validation samples, ECRIC and SCR 
 ECRIC 1999-2003 (derivation 
sample) 
SCR 2001-2015 (validation 
sample) 
Total number of participants 5,694 40,444 
Total time at risk (years) 31, 904 285,020 
Median follow-up (years) 5.65 6.41 
Number of breast cancer 
deaths 
737  4,922  
Number of other deaths 338 3,434 
Annual breast cancer mortality 
rate 
0.023 0.017 
Five-year breast cancer survival 
rate 
0.89 0.91 
Median age at diagnosis, years 58 61 
 Number (%) Number  (%) 
Age, years     
<35 111  2 506 1.3
35 to 49 1172  21 7094 17.5
50 to 64 2630  46 17054 42.2
65 to 74 1124 20 9975 24.7
75+ 657 12 5815 14.4
Nodal status     
0 3532  62 26718 66.1
1 741  13 5824 14.4
2 to 4 806  14 4513 11.2
5 to 9 380  7 1659 4.1
10+ 235  5 1484 3.7
Tumour size, mm     
<10 625  11 5542 13.7
10 to 19 2310  41 16057 39.7
20 to 29 1627  29 10888 26.9
30 to 49 845  15 6051 15
50+ 287  5 1906 4.7
Grade     
I 1005  18 5987 14.8
II 2927  51 19412 48
III 1762  31 14835 36.7
Estrogen receptor (ER) status     
ER negative 991  17 6311 15.6
ER positive 4703  83 34133 84.4
Adjuvant therapy     
Chemotherapy 1905  33 14589 36.1
Endocrine therapy 4268  75 30252 74.8
Combined chemoendocrine 1122  20 8875 21.9
Screen detected     
Yes 1621  28 15124 37.4
No 4073  72 25203 62.3
 
Source of ECRIC data: [1] 
 
 
Table 2 - Calibration - Predicted and observed deaths, full sample and sub-groups 
Follow-
up 5-year 10-year 
Group N A P 
Relative 
Mort. 
Diff. (%) 
Absolute 
Mort. Diff. 
(% point) N A P 
Relative 
Mort. Diff. 
(%) 
Absolute 
Mort. Diff. 
(% point) 
Total 32357 4684 4939 5.44 0.79 17106 5260 5157 -1.96 -0.6 
Age <35 426 70 74 5.47 0.94 249 71 79 11.77 3.21 
35-49 5851 547 664 21.35 2 3229 621 711 14.44 2.79 
50-64 13700 1246 1418 13.83 1.26 7227 1468 1514 3.11 0.64 
65-74 7645 1211 1220 0.71 0.12 3805 1366 1291 -5.5 -1.97 
>=75 4735 1610 1563 -2.91 -0.99 2596 1734 1562 -9.9 -6.63 
Nodes = 
0 20450 2004 2168 8.18 0.8 10377 2419 2342 -3.22 -0.75 
1 4798 692 712 2.83 0.41 2564 783 765 -2.25 -0.7 
2-4 4131 886 874 -1.38 -0.3 2414 999 960 -3.9 -1.62 
5-9 1492 471 480 1.95 0.6 887 491 476 -3.09 -1.69 
10+ 1271 559 627 12.02 5.32 724 486 532 9.43 6.32 
Tumour 
size <10 4552 304 338 11.17 0.75 2284 397 371 -6.41 -1.12
10-19 12289 1155 1280 10.75 1.01 6240 1410 1397 -0.88 -0.21 
20-29 8779 1422 1431 0.67 0.11 4736 1654 1532 -7.39 -2.58 
30-49 5161 1268 1279 0.88 0.22 2983 1313 1329 1.26 0.54
>=50 1577 535 611 14.17 4.81 863 486 527 8.31 4.71 
Grade I 4948 364 335 -7.79 -0.58 2796 554 468 -15.54 -3.07 
II 15058 1680 1801 7.16 0.8 7727 2160 2056 -4.84 -1.35 
III 12351 2640 2803 6.16 1.32 6583 2546 2634 3.43 1.33 
Screen 21059 3909 3929 0.52 0.09 11919 4349 4165 -4.24 -1.55 
Sympt. 11298 775 1009 30.26 2.07 5187 911 992 8.94 1.57 
ER- 5450 1437 1675 16.6 4.37 3037 1237 1307 5.62 2.29 
ER+ 26907 3247 3263 0.5 0.06 14069 4023 3850 -4.29 -1.23 
A: Actual deaths, P: Predicted deaths, Mort.diff, relative: Difference between actual and predicted as percentage of actual, absolute: Difference in 5/10 year mortality (% 
point 
  
 
 
Records retrieved 
from registry,           
n = 63,116 
Duplicate records, 
1,679 
  
Without 
duplicates, 
n = 61,437 
  
 Final complete 
case sample, 
n = 40,444 
<4 nodes sampled 
and node negative,  
10,378  
Ineligible cases , 
Advanced: 3,040 
Male: 345 
No surgery: 8,061 
Neo-adjuvant: 4,202 
(applied 
sequentially) 
  
Cases with missing 
prognostic 
variables, 
 5,345 
  
 Multiple imputation 
sample, 
n = 45,789 
  
 Sensitivity 
analysis sample, 
n = 30,066 


